As part of the agreement, Amgen will be granted rights to utilise Synaffix’s proprietary ADC technologies, GlycoConnect and HydraSpace, as well as select toxSYN linker-payloads for one ADC programme.
The company will also have the option to exercise exclusive research and commercial licences for an additional four programmes at a later date.
Amgen will be responsible for the research, development, manufacturing and commercialisation of the ADCs, with Synaffix continuing to hold responsibility for the manufacturing of components specifically related to its technologies.
